MedTrace Logo

DBM-1152A Inhalation Solution in Chinese Healthy Subjects

NCT07447141 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-03-03

No results posted yet for this study

Summary

This is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of DBM-1152A Inhalation Solution in healthy Chinese adult subjects.

Conditions

  • Health
  • Health Adult Subjects

Interventions

DRUG

DBM-1152A Inhalation Solution

Single dose via oral inhalation nebulization.

DRUG

Placebo

Single dose of blank vehicle via oral inhalation nebulization.

Sponsors & Collaborators

  • Livzon Pharmaceutical Group Inc.

    collaborator INDUSTRY

  • Joincare Pharmaceutical Group Industry Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yanmin Wu · Xuzhou Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-24
Primary Completion
2024-04-08
Completion
2024-04-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07447141 on ClinicalTrials.gov